← All trials
NCT01565148
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2012
- Primary completion
- Sep 1, 2013
- Completion date
- Dec 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 208
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- Johns Hopkins UniversityLead sponsor
- iCo Therapeutics Inc.Collaborator
- Elman Retina GroupOverall official - principal investigator
- Retina Institute of HawaiiOverall official - principal investigator
- Retina Macula InstituteOverall official - principal investigator
- Gulf Coast Eye InstituteOverall official - principal investigator
- Vitreo-Retinal Associates, MichiganOverall official - principal investigator
- Retinal Consultants of ArizonaOverall official - principal investigator
- Austin Retina AssociatesOverall official - principal investigator
- Black Hills Regional Eye InstituteOverall official - principal investigator
- East Bay Retina InstituteOverall official - principal investigator
- Florida Retina InstituteOverall official - principal investigator
- Retina Consultants HoustonOverall official - principal investigator
- Retina Group of FloridaOverall official - principal investigator
- Spokane Eye ClinicOverall official - principal investigator
- University of NebraskaOverall official - principal investigator
- Texas Retina Associates in ArlingtonOverall official - principal investigator
- Texas Retina Associates in DallasOverall official - principal investigator
- Johns Hopkins UniversitySponsor investigator
- Juvenile Diabetes Research FoundationCollaborator
- Retina Consultants of HawaiiOverall official - principal investigator
- Icahn School of Medicine at Mount SinaiOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.